VERTEX PHARMACEUTICALS INC / MA
VRTX · CIK 0000875320 · Pharmaceutical Preparations
About VERTEX PHARMACEUTICALS INC / MA
STRATEGIC TRANSACTIONS As part of our business strategy, we seek to license or acquire technologies, products, product candidates, and businesses that are aligned with our corporate and research and development strategies and that complement and advance our ongoing research and development efforts.
Business information sourced from SEC annual filing filed Feb 13, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.
Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.
Financial highlights
Latest qualifying annual SEC observations · USDHistorical financial performance
USD billions · Annual SEC observations · Choose a metric
Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.
Annual financial history
USD · Exact fiscal period ends| Period ended | Revenue | Net income | Operating income | Assets | Liabilities | Cash | Operating cash flow | Net margin |
|---|---|---|---|---|---|---|---|---|
| Dec. 31, 2025 | $12.00B | $3.95B | $4.17B | $25.64B | $6.98B | $5.08B | $3.63B | 32.9% |
| Dec. 31, 2024 | $11.02B | −$535.60M | −$232.90M | $22.53B | $6.12B | $4.57B | −$492.60M | -4.9% |
| Dec. 31, 2023 | $9.87B | $3.62B | $3.83B | $22.73B | $5.15B | $10.37B | $3.54B | 36.7% |
| Dec. 31, 2022 | $8.93B | $3.32B | $4.31B | $18.15B | $4.24B | $10.50B | $4.13B | 37.2% |
| Dec. 31, 2021 | $7.57B | $2.34B | $2.78B | $13.43B | $3.33B | $6.80B | $2.64B | 30.9% |
| Dec. 31, 2020 | $6.21B | $2.71B | $2.86B | $11.75B | $3.06B | $5.99B | $3.25B | 43.7% |
| Dec. 31, 2019 | $4.16B | $1.18B | $1.20B | $8.32B | $2.23B | $3.11B | $1.57B | 28.3% |
| Jan. 1, 2019 | — | — | — | $6.26B | — | — | — | — |
A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.
Company information
- Registered name
- VERTEX PHARMACEUTICALS INC / MA
- Ticker symbol
- VRTX
- CIK
- 0000875320
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC SIC code
- 2834
- Fiscal year end (MMDD)
- 1231
- Last SEC synchronization
- Nov 7, 2026 19:08 UTC
- Headquarters / business address
- 50 NORTHERN AVENUE
BOSTON, MA 02210 - Mailing address
- 50 NORTHERN AVENUE
BOSTON, MA 02210 - Business phone
- 6173416393
Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Last company information check: Nov 7, 2026 20:26 UTC. Official website, business descriptions and executive details require separate verification.
Latest SEC filings
Browse filings →| Form | Filed | Report period | Official source |
|---|---|---|---|
| 4 | Oct. 22, 2026 | Oct. 20, 2026 | View SEC filing ↗ |
| 4 | Oct. 19, 2026 | Oct. 15, 2026 | View SEC filing ↗ |
| 4 | Oct. 19, 2026 | Oct. 15, 2026 | View SEC filing ↗ |
| 4 | Sept. 10, 2026 | Sept. 8, 2026 | View SEC filing ↗ |
| 4 | Sept. 1, 2026 | Aug. 28, 2026 | View SEC filing ↗ |
| 4 | Aug. 31, 2026 | Aug. 27, 2026 | View SEC filing ↗ |
| 4 | July 23, 2026 | July 21, 2026 | View SEC filing ↗ |
| 4 | July 23, 2026 | July 21, 2026 | View SEC filing ↗ |
| 4 | July 17, 2026 | July 15, 2026 | View SEC filing ↗ |
| 4 | July 17, 2026 | July 15, 2026 | View SEC filing ↗ |
| 4 | July 7, 2026 | July 2, 2026 | View SEC filing ↗ |
| 4 | July 7, 2026 | July 2, 2026 | View SEC filing ↗ |
| 4 | July 6, 2026 | July 1, 2026 | View SEC filing ↗ |
| 4 | June 30, 2026 | June 26, 2026 | View SEC filing ↗ |
| 4 | June 23, 2026 | June 18, 2026 | View SEC filing ↗ |
| 4 | June 17, 2026 | June 15, 2026 | View SEC filing ↗ |
| 4 | June 9, 2026 | June 5, 2026 | View SEC filing ↗ |
| 4 | June 3, 2026 | June 1, 2026 | View SEC filing ↗ |
| 4 | June 2, 2026 | May 29, 2026 | View SEC filing ↗ |
| 4 | May 19, 2026 | May 15, 2026 | View SEC filing ↗ |
Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.